(A) Cumulative incidence of relapse in the whole RATHL cohort. Seven-year rate: 18.6% (95% CI, 16.4 to 21.0). (B) Cumulative incidence of relapse in randomly assigned PET patients: 7-year rates: 15.8% (95% CI, 12.7 to 19.5) ABVD and 18.5% (95% CI, 12.7 to 19.5) AVD; HR 1.20 (95% CI, 0.87 to 1.64), P = .25. ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AVD, doxorubicin, vinblastine, dacarbazine; HR, hazard ratio; PET, positron emission tomography.